Psoriasis hastalarında sigara içme durumu ile yaşam kalitesi arasındaki ilişkide hastalık şiddetinin aracı etkisi

Yıl 2022, Cilt: 47 Sayı: 2, 792 - 799, 30.06.2022

Mustafa Tosun Gülnur İlgün Nurperihan Tosun

https://doi.org/10.17826/cumj.1088577

Öz

Amaç: Bu çalışmada, psoriasis hastalarında sigara kullanımı ile yaşam kalitesi arasındaki ilişkinin incelenmesi ve bu ilişkide hastalık şiddetinin aracı rolünün araştırılması amaçlanmıştır.
Gereç ve Yöntem: Çalışmada 268 psoriasis hastasına kolayda örnekleme yöntemi ile ulaşılmıştır. Çalışmada hastaların yaşam kaliteleri “dermatoloji yaşam kalite indeksi (DLQI)” ve hastalık şiddetleri ise “psoriasis alan ve şiddet indeksi (PASI)” ile ölçülmüştür. Ayrıca bağımsız değişkenin (sigara içme) bağımlı değişken (yaşam kalitesi) üzerindeki etkisi, hem doğrudan etkisi hem de aracı değişken (hastalık şiddeti) aracılığıyla dolaylı etkisi süreç analizi ile incelenmiştir.
Bulgular: Sigara kullanma durumu cinsiyete, yaşa, medeni durumuna, mesleğe ve gelir gruplarına göre istatistiksel olarak anlamlı farklılık göstermektedir. Kadınların %17,02'si ve erkeklerin %44,09'u sigara içmektedir. Bekârların %19.74'ü ve evlilerin %33.85'i sigara içmektedir. İşsizlerin %20'si ve çalışanların %39,13'ü sigara içmektedir. Düşük gelirlilerin %17,76'sı, orta gelirlilerin %50,91'i ve yüksek gelirlilerin %40,98'i sigara içmektedir. Çalışmada temel olarak psoriasis hastalığında sigara içmenin yaşam kalitesi üzerinde doğrudan bir etkisinin olmadığı, ancak sigara içmenin hastalık şiddeti aracılığıyla yaşam kalitesi üzerinde dolaylı tam bir etkisinin olduğunu bulunmuştur.
Sonuç: Çalışmada sigara içmenin hem hastalık şiddeti aracılığıyla yaşam kalitesini olumsuz etkilediği bulunmuştur. Buna göre hastalar sigara içmenin hastalıkları üzerindeki etkisi konusunda bilgilendirilmesi önerilmektedir.

Anahtar Kelimeler

Psoriasis, Sigara, Yaşam Kalitesi

Mediating effect of disease severity on the relationship between smoking status and quality of life in psoriasis patients

Öz

Purpose: The aim of this study was to examine the relationship between smoking and quality of life and to investigate the mediating role of disease severity on this relationship in psoriasis patients.
Materials and Methods: In the study, 268 psoriasis patients were reached by the convenience sampling method. In the study, patients' quality of life was measured with “dermatology quality of life index (DLQI)” and disease severity was measured with “psoriasis area and severity index (PASI)”. The effect of the independent variable (smoking) on the dependent variable (quality of life), both directly and indirectly through the mediating variable (disease severity), was examined by process analysis.
Results: Smoking status shows statistically significant differences according to gender, age, marital status, occupation, and income groups. 17.02% of women and 44.09% of men smoke. 19.74% of single and 33.85% of married smoke. 20% of unemployed and 39.13% of employees smoke. 17.76% of low-income, 50.91% of middle-income, and 40.98% of high-income people smoke. This cross-sectional study revealed that smoking in psoriasis has no direct effect on the quality of life, but that smoking has a full indirect effect on the quality of life through disease severity.
Conclusion: In the study, it was found that smoking negatively affects the quality of life through both disease severity. Accordingly, it is recommended that patients be informed about the effect of smoking on their diseases.

Anahtar Kelimeler

Psoriasis, Smoking, Quality of Life

Kaynakça

• 1. WHO. "Global report on psoriasis." Geneva: World Health Organization. 2016.
• 2. Griffiths CE, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis. The Lancet. 2021; 397(10281): 1301-1315.
• 3. Seldin MF. The genetics of human autoimmune disease: a perspective on progress in the field and future directions. Journal of autoimmunity. 2015;64:1-12.
• 4. Dika E, Bardazzi F, Balestri R, Maibach HI. Environmental factors and psoriasis1. Environmental Factors in Skin Diseases. 2007;35:118-135.
• 5. Lee EB, Wu KK, Lee MP, Bhutani T, Wu JJ. Psoriasis risk factors and triggers. Cutis. 2018;102(5S):18-20.
• 6. Zeng J, Luo S, Huang Y, Lu Q. Critical role of environmental factors in the pathogenesis of psoriasis. The Journal of dermatology. 2017;44(8):863-872.
• 7. Barrea L, Nappi F, Di Somma C, et al. Environmental risk factors in psoriasis: the point of view of the nutritionist. International journal of environmental research and public health. 2016;13(7):743.
• 8. Raychaudhuri SP, Gross J. Psoriasis risk factors: role of lifestyle practices. Cutis. 2000; 66(5):348-352.
• 9. Jankovic S, Raznatovic M, Marinkovic J, Jankovic J, Maksimovic N. Risk factors for psoriasis: a case–control study. The Journal of Dermatology. 2009;36(6):328-334.
• 10. Heller MM, Lee ES, Koo JY. Stress as an influencing factor in psoriasis. Skin Therapy Lett. 2011;16(5):1-4.
• 11. Jankowiak B, Kowalewska B, Krajewska-Kułak E, Khvorik DF. Stigmatization and quality of life in patients with psoriasis. Dermatology and Therapy. 2020;10(2):285-296.
• 12. Roszkiewicz M, Dopytalska K, Szymanska E, Jakimiuk A, Walecka I. Environmental risk factors and epigenetic alternations in psoriasis. Annals of Agricultural and Environmental Medicine. 2020;27(3).
• 13. Amoruso GF, Nisticò SP, Iannone L, Russo E, Rago G, Patruno C, Bennardo L. Ixekizumab may improve renal function in psoriasis. In Healthcare (Vol. 9, No. 5, p. 543). 2021, May. Multidisciplinary Digital Publishing Institute.
• 14. Constantin MM, Bucur S, Mutu CC, et al. The Impact of Smoking on Psoriasis Patients with Biological Therapies in a Bucharest Hospital. Journal of Personalized Medicine. 2021;11(8):752.
• 15. Fortes C, Mastroeni S, Leffondré K, et al. Relationship between smoking and the clinical severity of psoriasis. Archives of dermatology. 2005;141(12):1580-1584.
• 16. Attwa E, Swelam E. Relationship between smoking‐induced oxidative stress and the clinical severity of psoriasis. Journal of the European Academy of Dermatology and Venereology. 2011;25(7):782-787.
• 17. Emre S, Metin A, Demirseren DD, Kilic S, Isikoglu S, Erel O. The relationship between oxidative stress, smoking and the clinical severity of psoriasis. Journal of the European Academy of Dermatology and Venereology. 2013;27(3):e370-e375.
• 18. Hayran Y, Yalçın B. Smoking habits amongst patients with psoriasis and the effect of smoking on clinical and treatment‐associated characteristics: A cross‐sectional study. International Journal of Clinical Practice. 2021:75(2):e13751.
• 19. Temiz SA, Özer İ, Ataseven A, Dursun R, Uyar M. The effect of smoking on the psoriasis: Is it related to nail involvement?. Dermatologic Therapy. 2020;33(6):e13960.
• 20. Choi J, Koo JY. Quality of life issues in psoriasis. Journal of the American Academy of Dermatology. 2003;49(2):57-61.
• 21. Tan X, Feldman SR, Balkrishnan R. Quality of life issues and measurement in patients with psoriasis. Psoriasis: targets and therapy. 2012;2(1):13-23.
• 22. Obradors M, Blanch C, Comellas M, Figueras M, Lizan L. Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Quality of Life Research. 2016;25(11):2739-2754.
• 23. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health and quality of life outcomes. 2006;4(1):1-7.
• 24. Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. Journal of the European Academy of Dermatology and Venereology. 2014;28(3):333-337.
• 25. Sampogna F, Tabolli S, Söderfeldt B, et al. Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators. Measuring quality of life of patients with different clinical types of psoriasis using the SF‐36. British Journal of Dermatology. 2006;154(5):844-849.
• 26. Jankovic S, Raznatovic M, Marinkovic J, et al. Health-related quality of life in patients with psoriasis. Journal of cutaneous medicine and surgery. 2011;15(1):29-36.
• 27. Çakmur H, Derviş E. The relationship between quality of life and the severity of psoriasis in Turkey. European Journal of Dermatology. 215;25(2):169-176.
• 28. Finlay AY, Khan G. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clinical and experimental dermatology. 1994;19(3): 210-216.
• 29. Öztürkcan S, Ermertcan AT, Eser E, Turhan Şahin M. Cross validation of the Turkish version of dermatology life quality index. International journal of Dermatology. 2006; 45(11):1300-1307.
• 30. Kayiran N, Korkmaz S, Özgöztasi O. Plak tip psoriasis hastalarinda sigaranin hastalik siddeti üzerine etkisi/Impact of smoking on disease severity in patients with plaque type psoriasis. Türkderm: Türk Deri Hastalıkları ve Frengi Arşivi= Turkderm: Turkish Archives of Dermatology and Venereology. 2015;49:19.
• 31. Higgins E. Alcohol, smoking and psoriasis. Clinical and experimental dermatology. 2000;25(2):107-110.
• 32. Ryder MI, Saghizadeh M, Ding Y, Nguyen N, Soskolne A. Effects of tobacco smoke on the secretion of interleukin‐1β, tumor necrosis factor‐α, and transforming growth factor‐β from peripheral blood mononuclear cells. Oral microbiology and immunology. 2002;17(6):331-336.
• 33. Ahdout J, Kotlerman J, Elashoff D, Kim J, Chiu MW. Modifiable lifestyle factors associated with metabolic syndrome in patients with psoriasis. Clin Exp Dermatol. 2012;37(5):477-83.
• 34. Demirseren DD, Emre S, Akoğlu G, Kılıç S, Metin A. (2012, September). Evaluation of effects of smoking and body mass index on clinical severity of psoriasis. In Proceedings of 21st Congress of the EADV (pp. 27-30).
• 35. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. Journal of the American Academy of Dermatology. 2006;55(5):829-835.
• 36. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not. Journal of molecular medicine. 2009;87(5):523-536.
• 37. Rakhesh, S. V., D'Souza, M., & Sahai, A. (2008). Quality of life in psoriasis: a study from south India. Indian Journal of dermatology, venereology and leprology, 74(6), 600-606.
• 38. Aghaei S, Moradi A, Ardekani GS. Impact of psoriasis on quality of life in Iran. Indian J Dermatol Venereol Leprol. 2009;75:220.